Immune Pharmaceuticals Announces Focu...

Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States

As a result of the merger, NASDAQ OMX Stockholm AB has advised, and the Company has agreed, to seek the transition of its Swedish listing to NASDAQ OMX First North Premier, which maintains access to Nordic country capital and liquidity for existing shareholders, while requiring less market specific regulation.

Start the conversation, or Read more at Sys-Con Media.

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

EpiCept Discussions

Title Updated Last By Comments
Gambling as a Mission impossible (Nov '09) Nov '09 Thorwald Olsson 1